Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights

<p>NEWARK, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) — Rain Oncology Inc. (Nasdaq: RAIN) (“Rain”), today announced it has entered into a definitive merger agreement whereby Pathos AI, Inc. (“Pathos”) will acquire Rain for $1.16 in cash per share plus a non-tradeable contingent value right (a “CVR”) for potential cash payments of up to approximately $0.17 […]</p>
<p>The post <a href="https://forextv.com/top-news/rain-oncology-enters-into-agreement-to-be-acquired-by-pathos-ai-for-1-16-in-cash-per-share-plus-contingent-value-rights/">Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>